Cancer Information

Prostate Cancer: Comprehensive Overview

Overview

Prostate cancer arises from abnormal growth of cells in the prostate gland, a small gland in men that produces seminal fluid. It is the second most common cancer in men worldwide. Most prostate cancers are adenocarcinomas. They may be indolent (slow-growing, localized) or aggressive (spreading quickly to bones and lymph nodes).

Prostate cancer arises from abnormal growth of cells in the prostate gland, a small gland in men that produces seminal fluid. It is the second most common cancer in men worldwide. Most prostate cancers are adenocarcinomas. They may be indolent (slow-growing, localized) or aggressive (spreading quickly to bones and lymph nodes).

Causes & Risk Factors

Known Causes

Prostate cancer develops due to genetic mutations and hormonal influences. Common causes include: - Mutations in tumor suppressor genes (BRCA1, BRCA2, TP53, PTEN) - Androgen-driven cell proliferation - Chronic inflammation or infection - Family history and inherited gene syndromes

Risk Factors

- Increasing age (most cases occur after 60 years)
- Family history of prostate cancer (first-degree relatives)
- Inherited mutations (BRCA1, BRCA2, HOXB13, Lynch syndrome)
- African ancestry (higher incidence and more aggressive disease)
- High-fat diet and obesity
- Smoking and sedentary lifestyle
- Prior exposure to radiation or certain chemicals

Symptoms & Early Signs

Early Warning Signs

Often asymptomatic in early stages. When present: - Difficulty urinating (weak stream, hesitancy, incomplete emptying) - Frequent urination, especially at night (nocturia) - Blood in urine (hematuria) or semen (hematospermia) - Erectile dysfunction - Pelvic discomfort

Common Symptoms

- Lower urinary tract symptoms (frequency, urgency, hesitancy, weak stream)
- Hematuria (blood in urine)
- Hematospermia (blood in semen)
- Erectile dysfunction
- Pain in hips, back, chest (bone metastases)
- Weakness or numbness in legs (spinal cord compression in advanced disease)
- Unexplained weight loss and fatigue

Diagnosis

- Digital rectal examination (DRE) - Prostate-specific antigen (PSA) blood test - Transrectal ultrasound (TRUS) guided biopsy - Multiparametric MRI (for localization and staging) - Bone scan, CT, PET scan (for metastatic disease) - Molecular testing: BRCA1/2, MSI, PTEN, DNA repair gene alterations

Staging Information

TNM staging system: - Stage I: Cancer confined to prostate, not palpable, PSA low - Stage II: Localized to prostate, larger or palpable tumor - Stage III: Tumor extends beyond prostate capsule or into seminal vesicles - Stage IV: Spread to regional lymph nodes or distant metastasis (commonly bone)

Treatment Information

Treatment Overview

- Active surveillance: For localized, low-risk disease - Surgery: Radical prostatectomy (open, laparoscopic, robotic-assisted) - Radiotherapy: External beam radiation, brachytherapy - Androgen deprivation therapy (ADT): LHRH agonists/antagonists, orchiectomy - Chemotherapy: Docetaxel, cabazitaxel in advanced disease - Targeted therapy: PARP inhibitors (olaparib, rucaparib) in BRCA/HRR-mutated disease - Immunotherapy: Sipuleucel-T, checkpoint inhibitors (in MSI-high tumors) - Palliative care for metastatic castration-resistant prostate cancer (mCRPC)

5-Year Survival Rate

N/A

Available Treatments

0

Treatment Options

Prognosis & Outlook

- Prognosis depends on stage, Gleason score/Grade Group, and PSA level - Localized disease has excellent prognosis (>95% 5-year survival) - Advanced metastatic disease has median survival 3–5 years with modern therapies - Newer agents (enzalutamide, abiraterone, apalutamide, darolutamide) improve survival in advanced cases

Prevention & Early Detection

- Maintain healthy diet (low fat, high in fruits/vegetables) - Exercise regularly and maintain healthy weight - Avoid smoking and limit alcohol - Screening: Discuss PSA testing with physician (typically ages 50–70; earlier for high-risk men) - Genetic counseling/testing for men with strong family history

Support & Resources

- Healthcare team: Urologists, oncologists, radiation oncologists, nurses - Patient support groups: Prostate Cancer Foundation, Us TOO International, ZERO – The End of Prostate Cancer - Online communities: CancerCare, Inspire Prostate Cancer Support - Counseling for psychological and sexual health issues - Physiotherapy and rehabilitation for post-surgery side effects (incontinence, erectile dysfunction)

Need More Information?

If you have questions about Prostate Cancer: Comprehensive Overview or would like to discuss your specific situation, our team is here to help.

Quick Facts

Cancer Type Prostate Cancer: Comprehensive Overview
Incidence Rate - Global incidence: ~1.4 million new cases annual
Mortality Rate - Global mortality: ~375,000 deaths annually - Fif
Survival Rate N/A
Treatment Options 0
Age Groups - Rare before age 40 - Most common after age 60 - Peak incidence between ages 65–75
Gender - Exclusively affects men

Get Expert Care

Our oncology team specializes in Prostate Cancer: Comprehensive Overview treatment and provides personalized care for every patient.

Schedule Consultation